whole human genome oligo microarray 44k (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
whole human genome oligo microarray 44k
Whole Human Genome Oligo Microarray 44k, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+whole+human+genome+oligo+microarray/pm38055384-77-1-7
Average 90 stars, based on 1 article reviews
Whole Human Genome Oligo Microarray 44k, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+whole+human+genome+oligo+microarray/pm38055384-77-1-7
Average 90 stars, based on 1 article reviews
whole human genome oligo microarray 44k - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Hybridization:Article Title: Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Article Snippet: Purpose: Medullary thyroid carcinoma (MTC), an aggressive rare tumor due to activating mutations in the proto-oncogene RET, requires new therapeutic strategies.. Sunitinib, a potent inhibitor of RET, VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor (PDGFR)a/b, has been reported as clinically effective in some patients with advanced MTC.. In this study, we examine molecular mechanisms of action of sunitinib and identify candidate soluble biomarkers of response. Labeling:Article Title: Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Article Snippet: Purpose: Medullary thyroid carcinoma (MTC), an aggressive rare tumor due to activating mutations in the proto-oncogene RET, requires new therapeutic strategies.. Sunitinib, a potent inhibitor of RET, VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor (PDGFR)a/b, has been reported as clinically effective in some patients with advanced MTC.. In this study, we examine molecular mechanisms of action of sunitinib and identify candidate soluble biomarkers of response. Microarray:Article Title: Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. Article Snippet: Purpose: Medullary thyroid carcinoma (MTC), an aggressive rare tumor due to activating mutations in the proto-oncogene RET, requires new therapeutic strategies.. Sunitinib, a potent inhibitor of RET, VEGF receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor (PDGFR)a/b, has been reported as clinically effective in some patients with advanced MTC.. In this study, we examine molecular mechanisms of action of sunitinib and identify candidate soluble biomarkers of response. Article Title: Are both distinct epithelial and stromal cells molecular analysis from phyllodes tumors versus fibroadenoma components affected in breast fibroepithelial progression? Article Snippet: .. The |
